NCT06740552

Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation

Effect of Evolocumab on Non-culprit Coronary Lesions in Patients With Multivessel Disease Following Acute Myocardial Infarction: A Target Trial Emulation

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,862 (actual)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this Target Trial Emulation (TTE) study is to evaluate the effect of evolocumab on clinical prognosis in patients with multivessel disease (MVD) following acute myocardial infarction (AMI) who have deferred non-culprit vessel. The main question it aims to answer is: Does evolocumab lower risks of major adverse cardiovascular events (MACE) in patients with deferred non-culprit vessel after AMI?

Detailed description

This study aims to investigate the potential prognostic benefits of evolocumab in patients with MVD after AMI at 2-year follow-up. The primary endpoint is MACE, defined as a composite of cardiac death, myocardial infarction, stroke, angina-driven coronary revascularization, and rehospitalization for heart failure. This is a multicentre, cohort-based TTE study and the target RCT is the FOURIER trial.

Conditions

• Multivessel Coronary Artery Disease
• Acute Myocardial Infarction (AMI)

Interventions

Type	Name	Description
DRUG	Evolocumab	Evolocumab 140mg every two weeks
DRUG	Lipid Lowering Medication	Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.

Timeline

• Start date: 2021-01-01
• Primary completion: 2024-12-31
• Completion: 2025-10-31
• First posted: 2024-12-18
• Last updated: 2026-02-02

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study